<DOC>
	<DOCNO>NCT01288092</DOCNO>
	<brief_summary>This prospective , multi-center , open-label , single arm , phase II study 2-stage design Bayesian interim monitoring investigate safety efficacy BEZ235 patient progressive metastatic HR+ HER2- breast cancer receive least one prior line endocrine therapy two three prior line chemotherapy metastatic disease . Patients stratify 3 group accord PI3K ( phosphatidylinositol 3-Kinase ) pathway activation status .</brief_summary>
	<brief_title>BEZ235 Trial Patients With HER2- ( Human Epidermal Growth Factor Receptor 2 Negative ) /HR+ ( Hormonal Receptor Positive ) Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female ≥ 18 year ECOG performance status ≤ 2 Histologically and/or cytologically confirm diagnosis breast cancer present metastatic disease ( hormone receptor positive HER2 negative ) Known PI3K activation status ( define PIK3CA ( Phosphoinositide3kinase , catalytic , alpha polypeptide ) mutation PTEN PTEN ( Phosphatase Tensin Homolog ) mutation/expression ) Prior treatment least one prior line endocrine therapy least two three prior line chemotherapy metastatic breast cancer Objective radiologically confirm progression disease prior treatment least one measurable lesion per RECIST Adequate bone marrow organ function Previous treatment PI3K and/or mTOR inhibitor Symptomatic Central Nervous System ( CNS ) metastases Concurrent malignancy malignancy last 5 year prior start study treatment Wide field radiotherapy ≤ 28 day limit field radiation palliation ≤ 14 day prior start study drug Active cardiac disease ( e.g . Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % , QTcF &gt; 480 msec screen ECGelectrocardiogram ( ECG ) , unstable angina pectoris , ventricular , supraventricular nodal arrhythmia ) Inadequately control hypertension Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BEZ235 Treatment start study treatment drug know risk induce Torsades de Pointes , moderate strong inhibitor inducer isoenzyme CYP3A4 , warfarin coumadin analogue , LHRH agonists History photosensitivity reaction drug Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>HR positive</keyword>
	<keyword>PI3K pathway</keyword>
	<keyword>2 prior line chemotherapy</keyword>
	<keyword>Metastatic Breast Cancer ( MBC )</keyword>
</DOC>